Nordic Bioscience receives Letter of Support from the U.S. Food and Drug Administration (FDA) for further study of the PRO-C3 biomarker assay in tumor fibrosis studies Paves way for further testing of the PRO-C3 biomarker assay, which identifies patients with hard to treat ‘fibrotic’ tumors, in further clinical trials US FDA recognizes need for a […]
Novel study is investigating dysregulation of the complement system during standard hemodialysis therapy in relation to patient health outcomes Glasgow, Scotland, 13 June 2023 – Invizius Limited (“Invizius”), a biotechnology company developing second generation therapies for a range of complement-driven autoimmune and inflammatory disorders, is pleased to announce that it has recruited its 300th patient […]
WiLD is a new and fast-growing professional network for women in senior positions across industry and academia in Danish life science A key objective is to provide professional, tailored mentoring programs for women in the life science business – from young talents to executives – in critical career transitions and WiLD has received a grant […]
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology currently focused on sexual health, today announces that the US Food and Drug Administration (“FDA”) has granted over the counter sale (“OTC”) Marketing Authorisation for MED3000, the Company’s breakthrough, topical gel formulation for the treatment […]
Stockholm, 9 June 2023 – Vicore Pharma Holding AB (publ) (“Vicore” or the “Company”) has completed directed share issuances of in total 29,875,000 shares at a subscription price of SEK 16.75 per share (the “Directed Issue”), through which the Company receives SEK 500 million before transaction costs. The subscription price was determined through an accelerated […]
